Enanta Pharmaceuticals (ENTA) Other Non-Current Assets (2012 - 2026)
Enanta Pharmaceuticals' (ENTA) quarterly Other Non-Current Assets came in at $3.4 million in Q1 2026, little changed YoY from $3.4 million in Q1 2025, and up 3512.9% on a QoQ basis from $93000.0 in Q4 2025.
Enanta Pharmaceuticals (ENTA) Other Non-Current Assets (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals (ENTA) has 15 years of Other Non-Current Assets data on file, last reported at $3.4 million in Q1 2026.
- Quarterly Other Non-Current Assets changed 0.0% year-over-year to $3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.4 million (changed 0.0% YoY) and the FY2025 annual result came in at $3.4 million, up 3474.47% from the prior year.
- Other Non-Current Assets rose to $3.4 million in Q1 2026, from $93000.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $4.0 million in Q3 2022 to a low of $92000.0 in Q1 2022.
- A 5-year average of $2.1 million and a median of $3.4 million in 2024 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2024 — Other Non-Current Assets plunged 97.63% — and 2025, when it surged 3474.47%.
- Tracing ENTA's Other Non-Current Assets over 5 years: stood at $701000.0 in 2022, then jumped by 466.05% to $4.0 million in 2023, then sank by 97.63% to $94000.0 in 2024, then dropped by 1.06% to $93000.0 in 2025, then surged by 3512.9% to $3.4 million in 2026.
- The last three Other Non-Current Assets figures came in at $3.4 million (Q1 2026), $93000.0 (Q4 2025), and $3.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Enanta Pharmaceuticals | 383.29 Mn | 193.78 Mn | - | 3.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.36 Mn |
| Mar 31, 2026 | 3.36 Mn |
| Dec 31, 2025 | 93,000.00 |
| Sep 30, 2025 | 3.36 Mn |
| Jun 30, 2025 | 3.36 Mn |
| Mar 31, 2025 | 3.36 Mn |
| Dec 31, 2024 | 94,000.00 |
| Sep 30, 2024 | 94,000.00 |
| Jun 30, 2024 | 3.36 Mn |
| Mar 31, 2024 | 3.97 Mn |
| Dec 31, 2023 | 3.97 Mn |
| Sep 30, 2023 | 3.97 Mn |
| Jun 30, 2023 | 830,000.00 |
| Mar 31, 2023 | 696,000.00 |
| Dec 31, 2022 | 701,000.00 |
| Sep 30, 2022 | 3.97 Mn |
| Jun 30, 2022 | 703,000.00 |
| Mar 31, 2022 | 92,000.00 |
| Dec 31, 2021 | 92,000.00 |
| Sep 30, 2021 | 608,000.00 |